Opportunity assessment: high. Enveda, a biotech startup that uses AI to find new drugs in plants and microbes, has raised a $311 million Series E at a $2 billion valuation. According to TechCrunch AI, Catalio Capital Management led the round, with Iconiq and others joining. That valuation is double what Enveda was worth 12 months ago.
One of AI’s biggest bets outside of chatbots just got a lot more expensive to ignore.
🎯 Situation Report
Here are the confirmed facts:
- Round: $311M Series E.
- Valuation: $2B, up 2x in a year.
- Lead investor: Catalio Capital Management. Iconiq also joined.
- Founder: Viswa Colluru, an early employee at Recursion Pharmaceuticals. He started Enveda in 2019.
- Mission: Use AI and other techniques to speed up drug discovery from natural sources.
- Clinical status: Several drugs are now being tested in patients.
The two named candidates stand out. One targets severe skin conditions. The other aims to help people keep weight off after they stop taking GLP-1s.
🌿 The Core Thesis
Enveda doesn’t design molecules from scratch in a lab. It works from the premise that nature has already built strong medicines, and that we just haven’t found most of them yet.
That idea has a long track record. Aspirin traces back to willow bark. Penicillin came from mold. The cancer drug paclitaxel came from the Pacific yew tree. The trouble has always been speed. Plants and microbes hold huge numbers of chemical compounds, and working out which ones do something useful in the body has historically taken years of slow lab work.
AI changes that math. Machine learning models can sort through huge chemical libraries, predict which compounds are worth chasing, and cut the list of candidates before anyone runs an expensive experiment. Enveda’s pitch is simple: pair nature’s chemical variety with AI’s ability to search it.
⚠️ Reality Check
TechCrunch AI points out an important caveat. AI hasn’t yet produced a single FDA-approved drug.
That’s the elephant in the room for the whole sector. Recursion, Insilico Medicine, and a growing list of others have moved AI-discovered candidates into human trials. None has crossed the finish line. Clinical trials are where most drugs fail, whether they came from AI or not. Faster discovery doesn’t guarantee a better success rate.
So Enveda’s $2B price tag is a bet on the future. Investors are paying for a pipeline and a platform, not proven results.
📡 Why This Matters
What stands out here is the GLP-1 angle. Drugs like Ozempic and Wegovy have taken over the weight-loss market, but many patients regain weight once they stop. A drug that helps people keep the weight off after coming off GLP-1s would go after one of the biggest and fastest-growing problems in medicine. That alone explains a lot of investor enthusiasm.
There’s also a bigger signal. Doubling a valuation in 12 months in biotech isn’t common. Money is moving toward AI companies with assets in the clinic, not just platform promises. The phrase “AI drug discovery” doesn’t get you funded by itself anymore. Patients in trials do.
🧭 Tactical Takeaways
If you follow AI in healthcare, keep an eye on these:
- Clinical readouts matter most. Trial data from Enveda’s skin and post-GLP-1 programs will show whether this approach actually works.
- The first AI-discovered FDA approval is still up for grabs. Whoever gets there first reshapes the whole category.
- The Recursion alumni network keeps growing. Colluru’s background shows how talent from early AI-bio companies is seeding the next wave.
- Expect more natural-product plays. A $2B valuation will pull more founders and funding into this corner of biotech.
🔭 Outlook
Enveda now has the cash to push more candidates into clinical trials. The next 12 to 24 months will show whether AI-guided searches of nature produce drugs that actually work in patients. If they do, the old lab-first drug discovery playbook will face serious pressure. Full details are available in the original TechCrunch AI report.